Impact of Second-Generation PDE 5 Inhibitor, Avanafil, on Retinal Function: Studies From Ex Vivo ERG
Investigative Ophthalmology & Visual Science · 2025
DOI: 10.1167/iovs.66.6.14 ↗Kurz gefasst
Fachartikel in der Zeitschrift Investigative Ophthalmology & Visual Science, 2025. Verfasst von Sama Saeid und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience and Biomedical Engineering, Aalto University, Espoo, Finland. Hauptthemen laut MEDLINE: Electroretinography, Phosphodiesterase 5 Inhibitors, Pyrimidines, Retina. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neuroscience and Biomedical Engineering, Aalto University, Espoo, Finland.
- John A. Moran Eye Center, University of Utah, Salt Lake City, Utah, United States.
Zitieren
APA
Saeid, S., Vinberg, F., & Koskelainen, A. (2025). Impact of Second-Generation PDE 5 Inhibitor, Avanafil, on Retinal Function: Studies From Ex Vivo ERG. Investigative Ophthalmology & Visual Science. https://doi.org/10.1167/iovs.66.6.14
Vancouver
Saeid S, Vinberg F, Koskelainen A. Impact of Second-Generation PDE 5 Inhibitor, Avanafil, on Retinal Function: Studies From Ex Vivo ERG. Investigative Ophthalmology & Visual Science. 2025. doi:10.1167/iovs.66.6.14
BibTeX
@article{Saeid2025,
author = {Saeid, Sama and Vinberg, Frans and Koskelainen, Ari},
title = {Impact of Second-Generation PDE 5 Inhibitor, Avanafil, on Retinal Function: Studies From Ex Vivo ERG},
journal = {Investigative Ophthalmology & Visual Science},
year = {2025},
doi = {10.1167/iovs.66.6.14}
}
EUVIMED